The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations

Soysal, Teoman; Eşkazan, Ahmet Emre; Serin, İstemi; Sadri, Sevil; Keskin, Dilek; Yurttaş, Nurgül Özgür; Berk, Selin; Özünal, Işıl Erdoğan; Salihoğlu, Ayşe; Ar, Muhlis Cem; Öngören, Şeniz; Başlar, Zafer; Özbek, Uğur; Aydın, Yıldız

doi:10.1016/j.clml.2019.03.028

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal response definitions stayed the same as they were in the previous recommendations. In the previous years, the warning response has undergone debate [15], and it was shown that especially the patients with late warning responses (BCR-ABL1 IS >0.1-1% at 12 months and/or thereafter) do relatively good in the long-term follow-up [16]. The warning and failure response definitions remain mostly unchanged except for the consideration of failure in the presence >10% BCR-ABL1 IS transcripts at three months of therapy if this value is confirmed in one to three months [4].…”

Section: Monitoringmentioning

confidence: 99%

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

Yılmaz

Eşkazan

2020

Expert Review of Hematology

Self Cite

View full text Add to dashboard Cite

Section: Monitoringmentioning

confidence: 99%

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

Yılmaz

Eşkazan

2020

Expert Review of Hematology

Self Cite

View full text Add to dashboard Cite

Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study

Algahtani

AlQahtany

2020

Journal of Infection and Public Health

View full text Add to dashboard Cite

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Hamza¹,

Shouman²,

Abdelfattah³

et al. 2022

DDDT

View full text Add to dashboard Cite

Background Imatinib is used to treat chronic myelogenous leukemia (CML). Variations in imatinib pharmacokinetics have been linked to genetic variations. That has an impact on imatinib response and adverse effects. Therefore, the aim of the study was to study bone pain as an adverse effect that occurs with imatinib and to investigate the risk factors for bone pain. Methods The relationship between the peak and trough plasma concentrations of imatinib with bone pain as one of the most frequently occurring adverse effects was examined. Multiple linear regression analysis and binary logistic regression analysis were used to measure the impact of various patients’ characteristics on both peak and trough imatinib concentrations and the risk of the occurrence of imatinib-induced bone pain. Results As a side effect of imatinib, approximately 15% of patients with CML who were taking it experienced bone pain. This side effect was linked to the imatinib peak and trough plasma levels. Imatinib trough concentration was also linked to gender and the gene SLCO1B3-334T > G (TT). There were significant associations between peak concentrations and gender as well as patient weight. Conclusion Higher peak and trough plasma concentrations of imatinib are linked with the risk of the occurrence of bone pain as a side effect of imatinib. Monitoring plasma concentrations of imatinib is useful to predict the bone pain of imatinib and to support quality of life in patients with CML.

show abstract

The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations

Cited by 3 publications

References 14 publications

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Contact Info

Product

Resources

About